Dr Barbara Pistilli

- Spécialité
- Oncologue médical, expert sein
- Titre
- Chef du comité de pathologie mammaire
- Hôpital
- Gustave Roussy (Villejuif)
- Derniers articles
-
- TROPION-Breast04: a randomized phase III study of neoadjuvant datopotamab deruxtecan (Dato-DXd) plus durvalumab followed by adjuvant durvalumab versus standard of care in patients with treatment-naïve early-stage triple negative or HR-low/HER2- breast cancer. (5 févr. 2025)
- Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer: Primary Results From TROPION-Breast01. (20 janv. 2025)
- Long-term behavioral symptom clusters among survivors of early-stage breast cancer: Development and validation of a predictive model. (1 janv. 2025)
- Immune checkpoint inhibitors for patients with metastatic triple-negative inflammatory breast cancer (INCORPORATE): An international cohort study. (1 déc. 2024)
- Unveiling the Potential of Cyclin-Dependent Kinases 4 and 6 Inhibitors Beyond Progression in Hormone Receptor Positive/Human Epidermal Growth Factor Negative Advanced Breast Cancer - A Clinical Review. (1 déc. 2024)